Interleukin-36 family as a novel regulator of inflammation in the barrier tissues

The interleukin-36 (IL-36) family was discerned in the superfamily of interleukin-1 (IL-1) ten years ago. This family includes three isoforms of IL-36α, IL-36β, IL-36γ, which have pro-inflammatory activity and a specific receptor antagonist, IL-36ra, which implements anti-inflammatory function. All of them bind to the same IL-1R6 receptor. The pro-inflammatory isoforms also involve an accessory IL-1RAcP protein into signaling; resulting into conduction of a signal into the cell via the assembling heterodimer receptor. In contrast, IL-36ra inhibits the formation of a heterodimer and blocks the signal transmission. The cytokines of the IL-36 family and appropriate receptors are normally expressed on epithelial cells in barrier tissues such as the respiratory, intestinal tract and skin. Like all cytokines of the IL-1 superfamily, IL-36 is synthesized as inactive form and requires activation, but not due to caspases, but being mediated by neutrophil enzymes, such as cathepsin G, proteinase-3, and elastase, which are constantly present in barrier tissues. In this regard, IL-36 is involved in homeostasis of barrier tissues. Apparently, the IL-36 cytokine system appeared in response to the developing ability of some microorganisms to avoid immune recognition and activation of innate immune response, and, in particular, the IL-1 pro-inflammatory system. An imbalance between the pro- and anti-inflammatory pathways readily causes inflammation in the corresponding tissue. This review discusses participation of cytokines from the IL-36 family in homeostasis of barrier tissues, as well as potential role of the IL-36 family in pathogenesis of bacterial, viral, and fungal skin diseases, atopic dermatitis, autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, ulcerative colitis and Crohn's disease. The role of IL-36 family cytokines in the immunopathogenesis of psoriasis has been well studied. This review is presenting the modern ideas about immune pathogenesis of psoriasis. The special role of cytokines from the IL-36 family was shown both for induction of psoriatic inflammation and evolving a positive feedback loop that supports and enhances the immune component of inflammation, which leads to progression of the disease. Moreover, modern methods of treating psoriasis are discussed, in particular, a possible promising approach to IL-36 blockade, or usage of recombinant IL-36ra for the treatment of psoriatic patients. Experimental studies in this area in mice provide some grounds for optimism.

interleukin-36, psoriasis, inflammation, infection, skin, dermatosis

1. Dermatovenerology. National manual. Brief Edition. Ed. Yu.S. Butov, Yu.K. Skripkina, O.L. Ivanova. Moscow: GEOTAR-Media, 2013. 896 p.

2. Kolobov A.A., Kondratieva E.V., Kudling T.V., Karasev M.M., Kalinin R.S., Protasov E.A., Nimiritsky P.P., Stefanov V.E., Aleksandrov G.V., Petrov A.V., Simbirtsev A.S. Development of a drug for the treatment of psoriasis based on the recombinant human interleukin-36 receptor antagonist (IL-36ra). Meditsinskaya Immunologiya = Medical immunology (Russia), 2017, Vol. 19, Special Iss., p. 271. (In Russ.) doi: 10.15789/1563-0625-2017-0.

3. Olisova O.Yu., Teplyuk N.P., Pinegin V.B. Modern methods of treatment of psoriasis. Russkiy meditsinskiy zhurnal = Russian Medical Journal, 2015, Vol. 23, no. 9, pp. 483-484. (In Russ.)

4. Talaev V.Yu. Mechanisms for controlling the migration of myeloid dendritic cells and Langerhans cells. Immunologiya = Immunology, 2012, Vol. 33, no. 2, pp. 104-112. (In Russ.)

5. Federal clinical guidelines. Dermatovenerology 2015: Diseases of the skin. Sexually transmitted infections. 5th ed., rev. and add. Moscow: Business Express, 2016. 415 p.

6. Bachmann M., Scheiermann P., Härdle L., Pfeilschifter J., Mühl H. IL-36γ/IL-1F9, an innate T-bet target in myeloid cells. J. Biol. Chem., 2012, Vol. 287, pp. 41684-41696.

7. Barksby H.E., Nile C.J., Jaedicke K.M., Taylor J.J., Preshaw P.M. Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide. Clin. Exp. Immunol., 2009, Vol. 156, no. 3, pp. 479-487.

8. Berglöf E., Andre R., Renshaw B.R., Allan S.M., Lawrence C.B., Rothwell N.J., Pinteaux E. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J. Neuroimmunol., 2003, Vol. 139, no. 1-2, pp. 36-43.

9. Boraschi D., Tagliabue A. The interleukin-1 receptor family. Semin. Immunol., 2013, Vol. 25, no. 6, pp. 394-407.

10. Boutet M.A., Bart G., Penhoat M., Amiaud J., Brulin B., Charrier C., Morel F., Lecon J.C., RolliDerkinderen M., Bourreille A., Vigne S., Gabay C.,Palmer G., le Goff B.,Blanchard F. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol., 2016, Vol. 184, no. 2, pp. 159-173.

11. Braegelmann J., Braegelmann C., Bieber T., Wenzel J. Candida induces the expression of IL-36γ in human keratinocytes: implications for a pathogendriven exacerbation of psoriasis? J. Eur. Acad. Dermatol. Venereol., 2018, Vol. 32, no. 11, pp. e403-e406.

12. Bronckers I.M., Paller A.S., van Geel M.J., van de Kerkhof P.C., Seyger M.M. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs., 2015, Vol. 17, no. 5, pp. 373-384.

13. Carrier Y., Ma H.L., Ramon H.E., Napierata L., Small C., O’Toole M., Young D.A., Fouser L.A., NickersonNutter C., Collins M., Dunussi-Joannopoulos K., Medley Q.G. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: Implications in psoriasis pathogenesis. J. Invest. Dermatol., 2011, Vol. 131, no. 12, pp. 2428-2437.

14. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. Autoimmun J., 2010, Vol. 34, no. 3, pp. 314-321.

15. Chiricozzi A., Guttman-Yassky E., Suárez-Fariñas M., Nograles K.E., Tian S., Cardinale I., Chimenti S., Krueger J.G. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Investig. Dermatol., 2011, Vol. 131, no. 3, pp. 677-687.

16. Chu M., Wong C.K., Cai Z., Dong J., Jiao D., Kam N.W., Lam C.W., Tam L.S. Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus. Molecules, 2015, Vol. 20, no. 10, pp. 19588-19604.

17. Chustz R.T., Nagarkar D.R., Poposki J.A., Favoreto S., Avila P.C., Schleimer R.P., Kato A. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol., 2011, Vol. 45, no. 1, pp. 145-153.

18. Ciccia F., Accardo-Palumbo A., Alessandro R., Alessandri C., Priori R., Guggino G., Raimondo S., Carubbi F., Valesini G., Giacomelli R., Rizzo A., Triolo G. Interleukin-36alpha axis is modulated in patients with primary sjogren’s syndrome. Clin. Exp. Immunol., 2015, Vol. 181, no. 2, pp. 230-238.

19. Clancy D.M., Henry C.M., Sullivan G.P., Martin S.J. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J., 2017, Vol. 284, no. 11, pp. 1712-1725.

20. Costelloe C., Watson M., Murphy A., McQuillan K., Loscher C., Armstrong M.E., Garlanda C., Mantovani A., O’Neill L.A., Mills K.H., Lynch M.A. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J. Neurochem., 2008, Vol. 105, no. 5, pp. 1960-1969.

21. de Bakker P.I., Raychaudhuri S. Interrogating the major histocompatibility complex with high-throughput genomics. Hum. Mol. Genet., 2012, Vol. 21, pp. R29-R36.

22. Debets R., Timans J.C., Homey B., Zurawski S., Sana T.R., Lo S., Wagner J., Edwards G., Clifford T., Menon S., Bazar J.F., Kastelein R.A .Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol., 2001, Vol. 167, no. 3, pp. 1440-1446.

23. d’Erme A.M., Wilsmann-Theis D., Wagenpfeil J., Hölzel M., Ferring-Schmitt S., Sternberg S., Wittmann M., Peters B., Bosio A., Bieber T., Wenzel J. IL-36γ. (IL-1F9) is a biomarker for psoriasis skin lesions. J. Invest. Dermatol., 2015, Vol. 135, no. 4, pp. 1025-1032.

24. di Cesare A., di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis J. Invest. Dermatol., 2009, Vol. 129, no. 6, pp. 1339-1350.

25. Dietrich D., Martin P., Flacher V., Sun Y., Jarrossay D., Brembilla N., Mueller C., Arnett H.A., Palmer G., Towne J., Gabay C. Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. Cytokine, 2016, Vol. 84, pp. 88-98.

26. di Marco M., Schuster H., Backert L., Ghosh M., Rammensee H.G., Stevanovic S. Unveiling the peptide motifs of HLA-C and HLA-G fromnaturally presented peptides and generation of binding prediction matrices. J. Immunol., 2017, Vol. 199, no. 8, pp. 2639-2651.

27. Dinarello C., Arend W., Sims J., Smith D., Blumberg H., O’Neill L., Goldbach-Mansky R., Pizarro T., Hoffman H., Bufler P., Nold M., Ghezzi P., Mantovani A., Garlanda C., Boraschi D., Rubartelli A., Netea M., van der Meer J., Joosten L., Mandrup-Poulsen T., Donath M., Lewis E., Pfeilschifter J., Martin M., Kracht M., Muehl H., Novick D., Lukic M., Conti B., Solinger A., Kelk P., van de Veerdonk F., Gabel C. IL-1 family nomenclature. Nat. Immunol., 2010, Vol. 11, no. 11, p. 973.

28. Dunn E., Sims J.E., Nicklin M.J., O’Neill L.A. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol., 2001, Vol. 22, no. 10, pp. 533-536.

29. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Update 2015. EDF in cooperation with EADV and IPC [Accessed on 1 Aug 2017]. Available at: http://www.euroderm.org/edf/index.php/edfguidelines/category/5-guidelinesmiscellaneous.

30. Farooq M., Nakai H., Fujimoto A., Fujikawa H., Matsuyama A., Kariya N., Aizawa A., Fujiwara H., Ito M., Shimomura Y. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum. Mutat., 2013, Vol. 34, no. 1, pp. 176-183.

31. Foster A.M., Baliwag J., Chen C.S., Guzman A.M., Stoll S.W., Gudjonsson J.E., Ward N.L., Johnston A. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol., 2014, Vol. 192, no. 12, pp. 6053-6061.

32. Franzke C.-W., Cobzaru C., Triantafyllopoulou A., Löffek S., Horiuchi K., Threadgill D.W., Kurz T., van Rooijen N., Bruckner-Tuderman L., Blobek C.P. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand–dependent terminal keratinocyte differentiation. J. Exp. Med., 2012, Vol. 209, no. 6, pp. 1105-1119.

33. Friedrich M., Tillack C., Wollenberg A., Schauber J., Brand S. IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17c in anti-TNF-induced psoriasiform skin lesions of patients with crohn’s disease. Inflamm. Bowel Dis., 2014, Vol. 20, no. 11, pp. 1891-1901.

34. Ganesan R., Raymond E.L., Mennerich D., Woska J.R., Caviness G., Grimaldi C., Ahlberg J., Perez R., Roberts S., Yang D., Jerath K., Truncali K., Frego L., Sepulveda E., Gupta P., Brown S.E., Howell M.D., Canada K.A., Kroe-Barrett R., Fine J.S., Singh S., Mbow M.L. Generation and functional characterization of anti-human and antimouse IL-36R antagonist monoclonal antibodies. MAbs, 2017, Vol. 9, no. 7, pp. 1143-1154.

35. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., Homey B.,Barrat F.J., Zal T., Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med., 2009, Vol. 206, no. 9, pp. 1983-1994.

36. Gardner J.K., Herbst-Kralovetz M.M. IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis. Cytokine, 2018, Vol. 111, pp. 63-71.

37. Geller S., Pulitzer M., Horwitz S.M., Moskowitz A.J., Myskowski P.L. Mycosis fungoides, psoriasis and antiPD-1 – a new aspect of known associations. J. Dtsch Dermatol. Ges., 2019, Vol. 17, no. 2, pp. 186-188.

38. Germán B., Wei R., Hener P., Martins C., Ye T., Gottwick C., Yang J., Seneschal J., Boniface K., Li M. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight, 2019, Vol. 4, no. 2, 123390. doi: 10.1172/jci.insight.123390.

39. Gilliet M., Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr. Opin. Immunol., 2008, Vol. 20, no. 4, pp. 401-407.

40. Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of Psoriasis: A comprehensive review. J. Autoimm., 2015, Vol. 64, pp. 66-73.

41. Harper E.G., Guo C., Rizzo H., Lillis J.V., Kurtz S.E., Skorcheva I., Purdy D., Fitch E., Iordanov M., Blauvelt A. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J. Investig. Dermatol., 2009, Vol. 129, no. 9, pp. 2175-2183.

42. Higgins J., Mutamba S., Mahida Y., Barrow P., Foster N. IL-36α induces maturation of Th1-inducing human MDDC and synergises with IFN-γ to induce high surface expression of CD14 and CD11c. Hum. Immunol., 2015, Vol. 76, no. 4, pp. 245-253.

43. Jensen L.E. Interleukin-36 cytokines may overcome microbial immune evasion strategies that inhibit interleukin-1 family signaling. Sci. Signal., 2017, Vol. 10, no. 492, eaan3589. doi: 10.1126/scisignal.aan3589.

44. Johnston A., Xing X., Guzman A.M., Riblett M., Loyd C.M., Ward N.L., Wohn C., Prens E.P., Wang F., Maier L.E., Kang S., Voorhees J.J., Elder J.T., Gudjonsson J.E. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol., 2011, Vol. 186, pp. 2613-2622.

45. Liu H., Archer N.K., Dillen C.A., Wang Y., Ashbaugh A.G., Ortines R.V., Kao T., Lee S.K., Cai S.S., Miller R.J., Marchitto M.C., Zhang E., Riggins D.P., Stibitz S., Geha R.S., Miller L.S. Staphylococcus aureus epicutaneous exposure drives skin inflammation via IL-36-mediated T cell responses. Cell Host Microbe, 2017, Vol. 22, no. 5, pp. 653-666.e5.

46. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med., 1998, Vol. 339, no. 8, pp. 520-532.

47. Medina-Contreras O., Harusato A., Nishio H., Flannigan K.L., Ngo V., Leoni G., Neumann P.A., Geem D., Lili L.N., Ramadas R.A., Chassaing B., Gewirtz A.T., Kohlmeier J.E., Parkos C.A., Towne J.E., Nusrat A., Denning T.L. Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J. Immunol., 2016, Vol. 196, no. 1, pp. 34-38.

48. Milora K.A., Uppalapati S.R., Sanmiguel J.C., Zou W., Jensen L.E. Interleukin-36β provides protection against HSV-1 infection, but does not modulate initiation of adaptive immune responses. Sci. Rep., 2017, Vol. 7, no. 1, p. 5799.

49. Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol., 2008, Vol. 8, no. 9, pp. 685-698.

50. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., Тalan D.A., EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med., 2006, Vol. 355, no. 7, pp. 666-674.

51. Mori K., Fujisawa T., Kusagaya H., Yamanaka K., Hashimoto D., Enomoto N., Inui N., Nakamura Y., Maekawa M., Suda T. Synergistic proinflammatory responses by IL-17A and tolllike receptor 3 in human airway epithelial cells. PLoS ONE, 2015, Vol. 10, no. 9, e0139491. doi: 10.1371/journal.pone.0139491.

52. Mulero J.J., Pace A.M., Nelken S.T., Loeb D.B., Correa T.R., Drmanac R., Ford J.F. IL1HY1: A novel interleukin-1 receptor antagonist gene. Biochem. Biophys. Res. Commun., 1999, Vol. 263, no. 3, pp. 702-706.

53. Nakagawa S., Matsumoto M., Katayama Y., Oguma R., Wakabayashi S., Nygaard T., Saijo S., Inohara N., Otto M., Matsue H, Nunez G., Nakamura Y. Staphylococcus aureus virulent PSMα peptides induce keratinocyte alarmin release to orchestrate IL-17-dependent skin inflammation. Cell Host Microbe, 2017, Vol. 22, no. 5, pp. 667-677.e5.

54. Nast A., Boehncke W.-H., Mrowietz U., Ockenfels H.-M., Philipp S., Reich K., Rosenbach T., Sammain A., Schlaeger M., Sebastian M., Sterry W., Streit V., Augustin M., Erdmann R., Klaus J., Koza J., Muller S., Orzechowski H.D., Rosumeck S., Schmid-Ott G., Weberschock T., Rzany B. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3-guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch Dermatol. Ges., 2012, Vol. 10, Suppl. 2, pp. S1-S95.

55. Nguyen T.T., Niyonsaba F., Ushio H., Akiyama T., Kiatsurayanon C., Smithrithee R., Ikeda S., Okumura K., Ogawa H. Interleukin-36 cytokines enhance the production of host defense peptides psoriasin and LL-37 by human keratinocytes through activation of MAPKs and NF-κB. J. Dermatol. Sci., 2012, Vol. 68, no. 1, pp. 63-66.

56. Nograles K.E., Krueger J.G. Anti-cytokine therapies for psoriasis. Exp. Cell Res., 2011, Vol. 317, no. 9, pp. 1293-1300.

57. Ortonne J., Chimenti S., Luger T., Puig L., Reid F., Trueb R.M. Scalp psoriasis: European consensus on grading and treatment algorithm. J. Eur. Acad. Dermatol. Venereol., 2009, Vol. 23, no. 12, pp. 1435-1444.

58. Perera G.K., di Meglio P., Nestle F.O. Psoriasis. Annu. Rev. Pathol., 2012, Vol. 7, pp. 385-422.

59. Pfaff C.M., Marquardt Y., Fietkau K., Baron J.M., Lüscher B. The psoriasis associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci. Rep., 2017, Vol. 7, no. 1, 15631. doi: 10.1038/s41598-017-15892-7.

60. Ramadas R.A., Ewart S.L., Medoff B.D., LeVine A.M. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am. J. Respir. Cell Mol. Biol., 2011, Vol. 44, no. 2, pp. 134-145.

61. Russell S.E., Horan R.M., Stefanska A.M., Carey A., Leon G., Aguilera M., Statovci D., Moran T., Fallon P.G., Shanahan F., Brint E.K., Melgar S., Hussey S., Walsh P.T. IL-36alpha expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunol., 2016, Vol. 9, no. 5, pp. 1193-1204.

62. Segre J.A. Epidermal barrier formation and recovery in skin disorders. J. Clin. Invest., 2006, Vol. 116, pp. 1150-1158.

63. Suárez-Fariñas M., Ungar B., Correa da Rosa J., Ewald D.A., Rozenblit M., Gonzalez J., Xu H., Zheng X., Peng X., Estrada Y.D., Dillon S.R., Krueger J.G., Guttman-Yassky E. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J. Allergy Clin. Immunol., 2015, Vol. 135, no. 5, pp. 1218-1227.

64. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., McCormick T.S., Cooper K.D. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol., 2005, Vol. 174, no. 1, pp. 164-173.

65. Swindell W.R., Beamer M.A., Sarkar M.K., Loftus S., Fullmer J., Xing X., Ward N.L., Tsoi L.C., Kahlenberg M.J., Liang Y., Gudjonsson J.E. RNA-Seq analysis of IL-1B and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature. Front. Immunol., 2018, Vol. 9, p. 80.

66. Takaishi M., Satoh T., Akira S., Sano S. Regnase-1, an immunomodulator, limits the IL-36/IL-36R autostimulatory loop in keratinocytes to suppress skin inflammation. J. Invest. Dermatol., 2018, Vol. 138, no. 6, pp. 1439-1442.

67. Tao X., Song Z., Wang C., Luo H., Luo Q., Lin X., Zhang L., Yin Y., Cao J. Interleukin 36α attenuates sepsis by enhancing antibacterial functions of macrophages. J. Infect. Dis., 2017, Vol. 215, no. 2, pp. 321-332.

68. Taylor S.L., Renshaw B.R., Garka K.E., Smith D.E., Sims J.E. Genomic organization of the interleukin-1 locus. Genomics, 2002, Vol. 79, no. 5, pp. 726-733.

69. Tortola L., Rosenwald E., Abel B., Blumberg H., Schäfer M., Coyle A.J., Renauld J.C., Werner S., Kisielow J., Kopf M. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest., 2012, Vol. 122, no. 11, pp. 3965-3976.

70. Towne J.E., Garka K., Renshaw B.R., Virca G.D., Sims J.E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcp to activate the pathway leading to NF-kappa B and MAPKs. J. Biol. Chem., 2004, Vol. 279, no. 14, pp. 13677-13688.

71. Towne J.E., Renshaw B.R., Douangpanya J., Lipsky B.P., Shen M., Gabel C.A., Sims J.E. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J. Biol. Chem., 2011, Vol. 286, no. 49, pp. 42594-42602.

72. Tsai Y.-C., Tsai T.-F. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther. Adv. Musculoskelet. Dis., 2017, Vol. 9, no. 11, pp. 277-294.

73. van de Veerdonk F.L., Stoeckman A.K., Wu G., Boeckermann A.N., Azam T., Netea M.G., Joosten L.A., van der Meer J.W., Hao R., Kalabokis V., Dinarello C.A. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad. Sci. USA, 2012, Vol. 109, no. 8, pp. 3001-3005. 74. Verma A.H., Zafar H., Ponde N.O., Hepworth O.W., Sihra D., Aggor F.E., Ainscought J.S., Ho J.,

74. Richardson J.P., Coleman B.M., Hube B., Stacey M., McGeachy M.J., Naglik J.R., Gaffen S.L., Moyes D.L. IL-36 and IL-1/IL-17 drive immunity to oral candidiasis via parallel mechanisms. J. Immunol., 2018, Vol. 201, no. 2, pp. 627-634.

75. Vigne S., Palmer G., Lamacchia C., Martin P., Talabot-Ayer D., Rodriguez E., Ronchi F., Sallusto F., Dinh H., Sims J.E., Garbay C. IL-36R ligands are potent regulators of dendritic and T cells. Blood, 2011, Vol. 118, no. 22, pp. 5813-5823.

76. Vigne S., Palmer G., Martin P., Lamacchia C., Strebel D., Rodriguez E., Olleros M.L., Vesin D., Garcia I., Ronchi F., Sallusto F., Sims J.E., Gabay C. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood, 2012, Vol. 120, no. 17, pp. 3478-3487.

77. Wang W., Yu X., Wu C., Jin H. IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis. Int. J. Med. Sci., 2017, Vol. 14, no. 10, pp. 1002-1007.

78. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., Gonzalez J., Krueger J.G., Lowes M.A. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Investig. Dermatol., 2009, Vol. 129, no. 1, pp. 79-88.

79. Zebrowska A., Wozniacka A., Juczynska K., Ociepa K., Waszczykowska E., Szymczak I., Pawliczak R. Correlation between IL36α and IL17 and activity of the disease in selected autoimmune blistering diseases. Mediators Inflamm., 2017, Vol. 2017, 8980534. doi: 10.1155/2017/8980534.